EPISODE · Dec 11, 2024 · 5 MIN
Day 4 Highlights from ASH 2024: Pediatric ALL, Epcoritamab, and a Next-Gen CLL Combo
from Curie: Healthcare in Focus
On Day 4 of ASH 2024, explore the remarkable 96% disease-free survival with Blincyto in pediatric ALL, deep responses with Epcoritamab in relapsed CLL, and the promise of a next-gen BCL2 inhibitor in a potent CLL combination. Tune in for transformative insights! Like what you hear? Download Curie from the App store for personalized insights.
NOW PLAYING
Day 4 Highlights from ASH 2024: Pediatric ALL, Epcoritamab, and a Next-Gen CLL Combo
No transcript for this episode yet
Similar Episodes
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m
Nov 12, 2025 ·35m
Oct 17, 2025 ·40m